A Novel Epigenetic Strategy to Concurrently Block Immune Checkpoints PD-1/PD-L1 and CD155/TIGIT in Hepatocellular Carcinoma

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu, Richard S. Finn, Julien Edeline et al. · The Lancet Oncology · 2018 · 2.5K citations

Open-label Phase 2, Hepatology, Medicine +8

The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level

Tomi Akinyemiju, Semaw Ferede Abera, Muktar Beshir Ahmed et al. · JAMA Oncology · 2017 · 2K citations · Full text

Global burden of primary liver cancer in 2020 and predictions to 2040

Harriet Rumgay, Melina Arnold, Jacques Ferlay et al. · Journal of Hepatology · 2022 · 1.8K citations · Full text

Global Burden, Primary Liver Cancer, Hepatic Disorders +12

Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation

Ming-Chun Lai, Zhe Yang, Lin Zhou et al. · Medical Oncology · 2011 · 604 citations

Hepatology, Medicine, Tumor Recurrence +10

Analysis of the receptor-ligand interactions in the natural killer–mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112)

Daniela Pende, Grazia Maria Spaggiari, Stefania Marcenaro et al. · Blood · 2004 · 360 citations